cabergoline Ligand page IUPHAR

cabergoline Ligand page IUPHAR

If you are not able to tolerate treatment with, or if it is not effective in your case, there are similar medications that can be considered, or other treatment options including pituitary surgery. No information is available on the excretion in breast milk in humans; however, mothers should be advised not to breast-feed in case of failed lactation inhibition/suppression by cabergoline. Since it prevents lactation, cabergoline should not be administered to mothers with hyperprolactinemic disorders who wish to breast-feed their infants. After cabergoline withdrawal, recurrence of hyperprolactinaemia is usually observed.

  • Additional appropriate investigations such as erythrocyte sedimentation rate, and serum creatinine measurements should be performed if necessary to support a diagnosis of a fibrotic disorder.
  • After parturition, when the mother elects not to breast feed the infant or when breast feeding is contraindicated due to medical reasons related to the mother or the new-born.
  • Patients should be careful when performing actions which require fast and accurate reaction during treatment initiation.
  • Access the world’s largest online veterinary resources, written by leading experts for 14 days.

Inhibition of lactation Administer 1mg as a single dose within the first 24 hours post partum. Risk limitation in cases of cabergoline-related impulse control disorders is reliant on frequent patient contact and the involvement of those closest to the patients. Clinical nurse specialists have an important role to play in picking up subtle but significant changes in mood, language and behaviour. Under in-patient observation due to apoplexy risk, he started cabergoline. Ali and his family were counselled regarding cabergoline’s effects and potential side effects.

Therapeutic Indications

As with other ergot derivatives, cabergoline should not be used with macrolide antibiotics (e.g. erythromycin) due to increased systemic bioavailability of cabergoline. • Renal insufficiency or ureteral/abdominal vascular obstruction that may occur with pain in the loin/flank and lower limb oedema as well as any possible abdominal masses or tenderness that may indicate retroperitoneal fibrosis. Erythrocyte sedimentation rate (ESR) has been found to be abnormally increased in association with pleural effusion/fibrosis. Chest x-ray examination is recommended in cases of unexplained ESR increases to abnormal values. History of pulmonary, pericardial and retroperitoneal fibrotic disorders. The safety and efficacy of cabergoline has not been established in subjects less than 16 years of age.


However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. This information is intended for patients receiving care in Brighton & Hove or Haywards Heath. After oral administration of the labelled compound, radioactivity was rapidly absorbed from the gastrointestinal tract as the peak of radioactivity in plasma was between 0.5 and 4 hours. Cabergoline should only be used during pregnancy if clearly indicated and after an accurate benefit/risk evaluation. Cabergoline should be discontinued if an echocardiogram reveals new or worsened valvular regurgitation, valvular restriction or valve leaflet thickening (see section 4.3).

Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ). Monitor patients during dose escalation to determine the lowest dose that produces the therapeutic response.